MedTrace Logo

Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML

NCT07511062 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2026-04-06

No results posted yet for this study

Summary

Axatilimab combined with Decitabine/Venetoclax for the treatment of TP53-mutated/deleted AML patients

Conditions

Interventions

DRUG

Decitabine

20mg/m2/d x5 days (induction \& consolidation)

DRUG

Venetoclax

400mg/d x14 days (induction); 400mg/d x7 days (consolidation)

DRUG

Axatilimab

Dose escalation, given on Days 1 and 15 of each cycle

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-01
Primary Completion
2029-08-01
Completion
2030-08-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07511062 on ClinicalTrials.gov